FDA accepts Ardelyx’s NDA resubmission for XPHOZAH
Pharma Leaders
MAY 18, 2023
The US Food and Drug Administration (FDA) has accepted Ardelyx’s resubmitted New Drug Application (NDA) for XPHOZAH (tenapanor) to control serum phosphate in adult patients with chronic kidney disease on dialysis who have had an insufficient response or intolerance to a phosphate binder therapy.
Let's personalize your content